Announcements Trials
Browse Landscape

Phase

Phase 2 1Phase 1/2 1

Status

Unknown 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Thoracic 2

Conditions

Carcinoma, Non-Small-Cell Lung 23Small Cell Lung Carcinoma 19Lung Neoplasms 10Neoplasms 4Adenocarcinoma of Lung 4NSCLC 3Thoracic Neoplasms 2Respiratory Tract Diseases 2Lung Diseases 2Advanced Non-squamous Non-small-cell Lung Cancer 2Uterine Cervical Neoplasms 1Stomach Neoplasms 1Small Cell Lung Cancer Limited Stage 1Small Cell Lung Cancer Extensive Stage 1SCLC 1Parkinson Disease 4, Autosomal Dominant Lewy Body 1PD-L1 Positive Non-small Cell Lung Cancer 1Ovarian Neoplasms 1Extensive Stage Small Cell Lung Cancer 1Esophageal Neoplasms 1Breast Neoplasms 1

Interventions

Carboplatin 9Pemetrexed 6Erlotinib Hydrochloride 5pembrolizumab 3osimertinib 3durvalumab 3camrelizumab 3Gemcitabine 3Gefitinib 3Cisplatin 3selpercatinib 2pralsetinib 2apatinib 2Radiosurgery 2taletrectinib 1sotorasib 1sintilimab 1repotrectinib 1patritumab 1necitumumab 1ficlatuzumab 1exemestane 1entinostat 1cobimetinib 1ceralasertib 1alectinib 1Vinorelbine 1Tyrosine Kinase Inhibitors 1Telescopes 1Radiotherapy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Respiratory Tract Diseases × apatinib × Thoracic × Clear all
NCT04133337 2019-10-21

Apatinib Combined With SHR-1210 Injection in the Treatment of Patients With Removable IB-IIIA NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 1/2 Unknown
20 enrolled
Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

NCT03389256 2018-01-03

Apatinib in the Treatment of Patients With EGFR T790M-Negative NSCLC

Sichuan Cancer Hospital and Research Institute

Phase 2 Unknown
144 enrolled
Thoracic

Lung Diseases, Neoplasms, Respiratory Tract Diseases, Thoracic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡